Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CS-060380 in Metabolic Dysfunction Associated Steatohepatitis: NCT07198386 Clinical Landscape Report 2026
9 min read
CS-060380 in Metabolic Dysfunction Associated Steatohepatitis: NCT07198386 Clinical Landscape Report 2026
18 September 2026
NCT07198386 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
Read →
MR001 in Triple Negative Breast Cancer: NCT07208149 Clinical Landscape Report 2026
9 min read
MR001 in Triple Negative Breast Cancer: NCT07208149 Clinical Landscape Report 2026
18 September 2026
NCT07208149 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Acamprosate Calcium in Amyotrophic Lateral Sclerosis: NCT07204977 Clinical Landscape Report 2026
9 min read
Acamprosate Calcium in Amyotrophic Lateral Sclerosis: NCT07204977 Clinical Landscape Report 2026
18 September 2026
NCT07204977 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
LY-4337713 in Pancreatic Intraductal Neoplasms: NCT07213791 Clinical Landscape Report 2026
9 min read
LY-4337713 in Pancreatic Intraductal Neoplasms: NCT07213791 Clinical Landscape Report 2026
18 September 2026
NCT07213791 clinical landscape for Pancreatic Intraductal Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
Read →
NNC-4005-0001 in Metabolic Dysfunction Associated Steatohepatitis: NCT07214870 Clinical Landscape Report 2026
9 min read
NNC-4005-0001 in Metabolic Dysfunction Associated Steatohepatitis: NCT07214870 Clinical Landscape Report 2026
18 September 2026
NCT07214870 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
Read →
Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania) in Recurrent Glioma: NCT07209241 Clinical Landscape Report 2026
9 min read
Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania) in Recurrent Glioma: NCT07209241 Clinical Landscape Report 2026
18 September 2026
NCT07209241 clinical landscape for Recurrent Glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Yttrium [90Y] chloride in Recurrent Glioblastoma: NL-OMON61160 Clinical Landscape Report 2026
9 min read
Yttrium [90Y] chloride in Recurrent Glioblastoma: NL-OMON61160 Clinical Landscape Report 2026
18 September 2026
NL-OMON61160 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Pembrolizumab in Squamous Cell Carcinoma of Head and Neck: NCT07218003 Clinical Landscape Report 2026
9 min read
Pembrolizumab in Squamous Cell Carcinoma of Head and Neck: NCT07218003 Clinical Landscape Report 2026
18 September 2026
NCT07218003 clinical landscape for Squamous Cell Carcinoma of Head and Neck: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
Read →
Ruxolitinib Phosphate in Renal Cell Carcinoma: NCT07219576 Clinical Landscape Report 2026
9 min read
Ruxolitinib Phosphate in Renal Cell Carcinoma: NCT07219576 Clinical Landscape Report 2026
18 September 2026
NCT07219576 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Amisodin in Amyotrophic Lateral Sclerosis: NCT07221240 Clinical Landscape Report 2026
9 min read
Amisodin in Amyotrophic Lateral Sclerosis: NCT07221240 Clinical Landscape Report 2026
18 September 2026
NCT07221240 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Nivolumab in Microsatellite instability-high colorectal cancer: NCT07223424 Clinical Landscape Report 2026
9 min read
Nivolumab in Microsatellite instability-high colorectal cancer: NCT07223424 Clinical Landscape Report 2026
18 September 2026
NCT07223424 clinical landscape for Microsatellite instability-high colorectal cancer: endpoints, sponsor, phase, geography, readouts, asset context and devel…
Read →
Terazosin Hydrochloride in Amyotrophic Lateral Sclerosis: NCT07224269 Clinical Landscape Report 2026
9 min read
Terazosin Hydrochloride in Amyotrophic Lateral Sclerosis: NCT07224269 Clinical Landscape Report 2026
18 September 2026
NCT07224269 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →